AKTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aktis Oncology Inc (AKTS) does not present a strong buy opportunity for a beginner, long-term investor at this time. The stock is experiencing a bearish trend with no immediate positive signals from technical indicators or proprietary trading signals. While analysts are optimistic about the company's long-term potential in radiopharmaceutical therapies, the current price trend and lack of significant positive catalysts suggest waiting for a better entry point.
The stock is in a bearish trend with MACD showing negative expansion, RSI at 34.123 in the neutral zone, and moving averages indicating a downward trajectory (SMA_200 > SMA_20 > SMA_5). The price is nearing the support level of 17.235, with resistance at 18.69 and higher levels.
The company's technology is seen as innovative and potentially first-in-class.
The stock has seen a significant price decline (-5.47% in regular trading and -1.98% pre-market). Technical indicators and trading trends show no immediate bullish sentiment. No recent news or influential trades have been reported to drive short-term momentum.
In Q4 2024, revenue remained flat at $933,000, while net income improved but remained negative at -$12.056M (+43.29% YoY). EPS improved significantly to -0.96 (+464.71% YoY), and gross margin remained at 100%. While there is improvement in losses, the company is still not profitable.
Analysts are highly positive, with multiple buy ratings and price targets between $30 and $34. They highlight the company's potential in radiopharmaceutical therapies and its innovative miniprotein platform. However, these are long-term projections and do not align with the current bearish price trend.
